Megestrol: The Complete 2026 Guide to Megestrol Acetate, Uses, Dosing & Safety
Megestrol—and its pharmaceutical form, Megestrol Acetate—is one of the most intriguing molecules in modern medicine.
It wears two hats: a potent hormonal weapon against certain cancers and a powerful appetite stimulant that helps patients regain weight and vitality as their bodies waste away.
Yet, this progestin is also classified as a high-risk medication by major health authorities, carrying a range of side effects and critical warnings that every prescriber, patient, and caregiver must understand.
In this complete guide—our definitive resource on Megestrol and Megestrol Acetate—we’ll walk you through every crucial facet of this medication.
Whether you’re a healthcare professional, a patient, a pharmacy compounder, or a pharmaceutical sourcing manager, you’ll find evidence-based answers, clinical insights, and real-world tips presented in a clear, actionable way.
Let’s dive in.
What is Megestrol and What is Megestrol Acetate?
Megestrol is the generic name for a synthetic derivative of the naturally occurring steroid hormone progesterone.
In medical practice, it is almost exclusively used as Megestrol Acetate, the acetate ester that confers the molecule’s pharmaceutical stability, bioavailability, and therapeutic activity.
Chemical Identity
Megestrol acetate is a white, crystalline solid with the chemical name 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione. Its empirical formula is C₂₄H₃₂O₄ and its molecular weight is 384.51 g/mol. The drug is practically insoluble in water (2 µg/mL at 37 °C) but dissolves better in plasma (24 µg/mL), which favors formulating it as a suspension rather than a simple solution.
Brand Names & Formulations
Megestrol acetate is sold under several brand names worldwide, most notably:
Megace® (tablets)
Megace® ES (extended-release oral suspension)
Generic manufacturers also supply tablets of 20 mg and 40 mg, as well as oral suspensions containing 40 mg/mL or 125 mg/mL of micronized megestrol acetate (API).
Drug Classification
Megestrol acetate belongs to two pharmacological classes:
Progestogens / Progestins – synthetic compounds that mimic the action of progesterone.
Hormones / Antineoplastics – agents that interfere with hormone-driven tumor growth.
Because of its glucocorticoid-like properties, it also lies at the border of corticosteroid pharmacology, which helps explain many of its side effects.
Key takeaway: “Megestrol” and “Megestrol Acetate” are used interchangeably in clinical settings. The acetate form is the one you’ll find in pharmacies, hospitals, and compounding labs.
What is Megestrol Used For?
Megestrol has earned a unique dual indication: it treats certain cancers and combats severe weight loss.
Let’s break down the approved and off-label uses.
FDA-Approved Indications
In the United States, the Food and Drug Administration (FDA) has approved megestrol acetate for:
Palliative treatment of advanced breast cancer (recurrent, inoperable, or metastatic).
Palliative treatment of advanced endometrial (uterine) cancer (recurrent, inoperable, or metastatic).
Treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS.
Other Clinically Recognized Uses
Physicians can lawfully prescribe megestrol for conditions beyond the FDA label when medical evidence supports it.
These include:
Cancer-related anorexia-cachexia syndrome (CACS) in patients with lung, colorectal, pancreatic, and head-and-neck cancers.
Appetite stimulation in palliative care for any terminal illness where weight loss threatens quality of life.
Prostate cancer – by suppressing testosterone production via gonadotropin inhibition.
Endometrial hyperplasia and certain gynecological disorders.
Hot flashes in menopausal women (unlicensed but occasionally used).
Important: When prescribed for non‑FDA‑approved indications, patients should discuss the rationale and evidence with their physician.
What is Megestrol Acetate Used For?
Since Megestrol Acetate is the pharmaceutical form of Megestrol, its uses mirror those described above.
However, the oral suspension (Megestrol Acetate Oral Suspension, USP) warrants special attention, as it was specifically developed to stimulate appetite.
Megestrol Acetate Oral Suspension – The Appetite Booster
The suspension formulation was approved by the FDA in 1993 for AIDS‑related wasting and has become the go‑to form for cachexia management because:
It allows flexible, high‑dose administration (up to 800 mg/day) that would be impractical with tablets.
It achieves reliable plasma levels in cachectic patients who may have difficulty swallowing or absorbing tablets.
Oncology Use
In cancer care, Megestrol Acetate tablets are most often used:
Breast cancer: 160 mg/day (40 mg four times daily).
Endometrial cancer: 40–320 mg/day in divided doses.
Treatment is typically continued for at least 2 months to assess effectiveness.
Why is Megestrol a High-Risk Medication?
The Institute for Safe Medication Practices (ISMP) and many hospital systems classify Megestrol as a high-alert medication because of its potential to cause serious harm when used in error or without adequate monitoring.
Several factors contribute to this classification:
1. Thromboembolic Risk
Megestrol acetate significantly increases the risk of deep venous thrombosis (DVT) and pulmonary embolism—complications that can be fatal. In a randomized trial comparing megestrol with dexamethasone, DVT occurred in 5% of megestrol patients versus 1% with dexamethasone (P = .06).
2. Adrenal Suppression
Megestrol possesses approximately 25% of the glucocorticoid activity of cortisol on a weight‑for‑weight basis. This means it can suppress the hypothalamic‑pituitary‑adrenal (HPA) axis, leading to secondary adrenal insufficiency. When the drug is stopped abruptly, patients may experience a life‑threatening adrenal crisis.
3. Hyperglycemia and Diabetes
Glucocorticoid effects can induce insulin resistance and worsen glycemic control in diabetic patients. Some patients require a 10‑fold increase in daily insulin requirements.
4. Pregnancy Category Contraindication
Megestrol is contraindicated during pregnancy (FDA Pregnancy Category X in some labeling). Animal studies show fetal harm, and it must not be used by women who are or may become pregnant.
5. Immunosuppression
Long‑term treatment may increase the risk of respiratory infections, as seen in animal toxicology studies.
Clinical Bottom Line
Megestrol is not a benign drug.
Every prescription requires a careful risk‑benefit assessment, baseline and periodic monitoring of glucose, adrenal function, and coagulation status, and clear patient education about danger signs.
How Does Megestrol Work? (Mechanism of Action)
Megestrol acetate works through multiple, overlapping mechanisms depending on the condition being treated.
1. Progestin Receptor Activation
Like natural progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in reproductive tissues. The ligand‑receptor complex translocates to the cell nucleus, where it binds to specific DNA sequences and alters gene transcription.
2. Antiestrogenic Effect (Cancer Indication)
In hormone‑sensitive breast and endometrial cancers, megestrol exerts an anti‑estrogenic action by:
Suppressing pituitary gonadotropin secretion (LH and FSH).
Reducing ovarian estrogen production.
Downregulating estrogen receptors in tumor cells.
Directly interfering with estrogen‑responsive gene expression.
3. Direct Cytotoxicity
Pharmacologic doses of megestrol not only decrease the number of hormone‑dependent cancer cells but also exert a direct cytotoxic effect on tumor cells.
4. Appetite Stimulation (Cachexia Indication)
The exact mechanism for appetite enhancement is not fully understood. Leading hypotheses include:
Modulation of neuropeptide Y and other appetite‑regulating cytokines.
Glucocorticoid receptor activation can centrally increase appetite.
Suppression of catabolic cytokines (e.g., tumor necrosis factor‑alpha, interleukins) that drive cachexia.
Did you know? Megestrol’s weight gain effect is driven by increased food intake, not fluid retention. It stimulates genuine caloric consumption, which is why it is so valuable in wasting syndromes.
What Are Megestrol Side Effects?
Megestrol’s side effect profile reflects its dual progestin‑glucocorticoid nature.
Clinicians must distinguish between common nuisance effects and serious adverse events.
Common Side Effects (≥5% of patients)
| Side Effect | Frequency | Notes |
|---|---|---|
| Weight gain | Very common | Due to increased appetite, not edema |
| Nausea, vomiting, diarrhea, gas | Common | It can be reduced by taking it with food |
| Impotence / decreased libido | Common | Hormonal suppression |
| Rash | Common | Usually mild |
| Hypertension | 1–3% | Monitor blood pressure |
| Asthenia (weakness) | 1–3% | May improve over time |
| Insomnia | 1–3% | |
| Headache | 1–3% | |
| Vaginal bleeding/spotting | 1–3% | Breakthrough bleeding |
| Hyperglycemia | 1–3% | Critical in diabetics |
Adapted from clinical trial data.
Serious Adverse Events (require immediate medical attention)
Venous thromboembolism – DVT, pulmonary embolism (some cases fatal).
Adrenal insufficiency – especially after abrupt withdrawal.
Severe cardiomyopathy – rare but documented.
Seizures – reported in 1–3% of patients.
Severe allergic reactions – anaphylaxis, angioedema.
Tumor flare with or without hypercalcemia.
Glucose intolerance / new‑onset diabetes.
Carpal tunnel syndrome – attributed to fluid shifts.
Mood changes – depression, mood swings.
Patients should be counseled to seek urgent care for leg pain/swelling, sudden shortness of breath, chest pain, severe headache, vision changes, or signs of infection.
Overdose Safety Note
Remarkably, megestrol shows low acute toxicity. Studies administering 1,600 mg/day produced no serious unexpected effects, and single oral doses of 5 g/kg in mice were non‑toxic. Dialysis is not effective due to low solubility.
Megestrol Dosage and Administration
Dosing is highly indication‑specific.
Below are the evidence‑based regimens drawn from FDA labeling and major clinical guidelines.
For Cancer‑Related Anorexia/Cachexia (AIDS or Cancer)
| Formulation | Recommended Initial Dosage | Frequency |
|---|---|---|
| Megestrol Acetate Oral Suspension (40 mg/mL) | 800 mg (20 mL) per day | Once daily |
| Megace® ES (125 mg/mL) | 625 mg (5 mL) per day | Once daily |
Shake the container well before each use. Clinical trials have tested doses from 100 mg to 1,600 mg/day, but the 800 mg/day level appears to provide the optimal balance of efficacy and tolerability.
For Breast Cancer
160 mg/day (40 mg tablet four times daily).
For Endometrial Cancer
40 – 320 mg/day in divided doses.
For Prostate Cancer (off‑label)
120 mg once daily in combination with diethylstilbestrol 0.1 mg.
Duration of Therapy
A minimum of 2 months of continuous treatment is considered an adequate trial for cancer indications.
For cachexia, response (weight gain) can be assessed as early as 3–4 weeks, but the maximum effect may take 8–12 weeks.
Missed Dose Instructions
If you miss a dose, take it as soon as you remember, within the same day.
If a full day has passed, skip the missed dose and resume the normal schedule.
Never double the dose.
Special Populations
Elderly: Start at the low end of the dosing range due to decreased renal/hepatic function.
Renal Impairment: Megestrol is substantially renally excreted; monitor for toxic reactions.
Pregnancy: Contraindicated (Pregnancy Category X). Obtain a negative pregnancy test before initiating in women of reproductive potential.
Breastfeeding: Discontinue nursing due to potential adverse effects on the newborn.
What Happens When You Stop Taking Megestrol?
Abrupt discontinuation of megestrol—especially after prolonged use—can trigger a constellation of unpleasant and potentially dangerous withdrawal effects.
Adrenal Insufficiency – The Critical Concern
Because megestrol suppresses the HPA axis, the adrenal glands may temporarily “forget” how to produce cortisol independently.
When the drug is suddenly removed, patients can develop secondary adrenal insufficiency, characterized by:
Severe fatigue and weakness
Nausea, vomiting, dizziness
Hypotension and electrolyte disturbances
In severe cases, cardiovascular collapse.
In a documented case, a patient who abruptly stopped megestrol after 4 years of treatment showed low basal cortisol and a blunted response to cosyntropin stimulation, confirming adrenal suppression.
Other Withdrawal Symptoms
Mood depression and anxiety
Loss of appetite (the opposite of the desired effect)
Energy loss
Palpitations and sweating
Weight loss
Sexual dysfunction (hypogonadism, erectile dysfunction).
Safe Tapering
To minimize withdrawal effects, clinicians typically employ a gradual dose reduction over several weeks.
If long‑term therapy has exceeded 2–3 months, an ACTH stimulation test may be warranted to assess adrenal function.
How Long Does Megestrol Stay in Your System?
Understanding megestrol’s pharmacokinetics is essential for timing lab tests, managing drug interactions, and planning surgery.
Half‑Life and Clearance
Mean elimination half‑life: 20–50 hours in healthy subjects. Some sources report a range of 15–100 hours, reflecting inter‑individual variability.
Excretion: Approximately 66.4% of a radiolabeled dose is recovered in urine within 10 days, and 19.8% in feces.
Time to Steady State
With daily dosing, steady‑state plasma levels are achieved after approximately 5 half‑lives, which translates to 4–10 days (100–250 hours).
Time to Complete Elimination
As a rule of thumb, a drug is considered eliminated after 4–5 half‑lives. For megestrol, that means the drug will be largely cleared from the body within 3–10 days after the last dose. However, trace metabolites may be detectable longer.
Practical Implications
Surgery: Discontinue megestrol at least 5–7 days before elective procedures to reduce the risk of thromboembolism.
Pregnancy planning: Women should wait at least 2–4 weeks after stopping the drug before attempting conception.
Lab testing: Allow at least a 2‑week washout for accurate adrenal function assessment.
Megestrol Precautions and Drug Interactions
If you’re managing a patient on megestrol—or taking it yourself—these precautions are non‑negotiable.
Drug‑Drug Interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| Warfarin | Increased INR, bleeding risk | Monitor INR closely; adjust warfarin dose |
| Indinavir | Decreased indinavir Cₘₐₓ (~32%) and AUC (~21%) | Monitor HIV viral load; consider indinavir dose adjustment |
| Zidovudine, Rifabutin | No clinically significant PK alteration | Standard dosing |
| CYP450 Inducers (rifampicin, phenytoin, carbamazepine) | May lower megestrol levels | Effectiveness may be reduced; monitor response |
Medical Conditions Requiring Caution
History of thromboembolic disease – increased DVT risk.
Diabetes mellitus – anticipate worsening glycemic control.
Heart failure – fluid retention potential.
Hepatic impairment – drug metabolism may be altered.
Renal impairment – drug accumulates; higher risk of toxicity.
Patient Monitoring Schedule
| Parameter | Baseline | During Treatment |
|---|---|---|
| Weight | ✓ | Weekly |
| Blood glucose | ✓ | Every 2–4 weeks |
| INR (if on warfarin) | ✓ | Every 1–2 weeks |
| Morning cortisol / ACTH | Consider | If on prolonged therapy |
| Blood pressure | ✓ | Every visit |
| Signs/symptoms of DVT | ✓ | At each visit |
| Pregnancy test (females of childbearing potential) | ✓ | As indicated |
Megestrol vs. Dexamethasone
One of the most clinically relevant comparisons is between megestrol acetate and corticosteroids like dexamethasone, both used for appetite stimulation in cancer cachexia.
The Landmark Head‑to‑Head Trial
A practice‑changing randomized trial compared megestrol acetate 800 mg/day with dexamethasone 0.75 mg four times daily and fluoxymesterone 10 mg twice daily in patients with cancer anorexia/cachexia.
Key findings:
Both megestrol and dexamethasone produced similar increases in appetite and weight gain.
Dexamethasone caused significantly more steroid‑type toxicity and a higher discontinuation rate due to toxicity (36% vs. 25%, P = .03).
Megestrol had a higher thrombotic risk (5% DVT vs. 1% with dexamethasone, P = .06).
Fluoxymesterone was clearly inferior, with less improvement in appetite and a more toxic profile.
Glucocorticoid Activity Profile
At the receptor level, megestrol acetate has about 25% of cortisol’s glucocorticoid activity, while medroxyprogesterone acetate (another progestin) has about 50%. This explains why megestrol can cause Cushingoid features but with less severity than full‑dose corticosteroids.
Clinical Decision Framework
| Factor | Favor Megestrol | Favor Dexamethasone |
|---|---|---|
| Thromboembolic risk | Higher | Lower |
| Steroid toxicity (myopathy, skin fragility, immunosuppression) | Lower | Higher |
| Long‑term tolerability | Better | Worse |
| Onset of appetite effect | 2–4 weeks | Days |
| Cost | Generally higher | Lower |
Bottom line:
For patients requiring prolonged appetite stimulation (>4–6 weeks), megestrol often proves more sustainable.
For short‑term needs or patients with high thrombotic risk, a corticosteroid may be preferable.
Compounding Guidelines for Megestrol Acetate
Pharmacists in compounding settings must follow precise methodologies to produce stable, bioavailable megestrol acetate suspensions.
Official Formulation
Megestrol Acetate Oral Suspension, USP is supplied as a 40 mg/mL micronized suspension. The official inactive ingredients include:
Citric acid (anhydrous)
Lemon‑lime flavor
Poloxamer 124 (surfactant)
Propylene glycol
Purified water
Sodium benzoate (preservative)
Sodium citrate dihydrate
Sucrose
Xanthan gum (suspending agent)
pH adjusted with 10% citric acid or sodium citrate to pH 3.0–4.7.
Flocculated Suspension Technology
Novel patented formulations describe a stable, flocculated suspension comprising megestrol acetate, a compound selected from polyethylene glycol, propylene glycol, glycerol, or sorbitol, and a surfactant. The flocculated structure ensures uniform dose distribution upon shaking.
Compounding Best Practices
Start with micronized API – particle size directly impacts bioavailability.
Use a validated suspending vehicle – e.g., CMC‑Na (carboxymethylcellulose sodium) at 5 mg/mL for research formulations.
Control pH – megestrol acetate is most stable at pH 3.0–4.7.
Include a preservative – e.g., sodium benzoate 0.1% w/v.
Assign beyond‑use date – compounded suspensions are typically stable for 30–60 days refrigerated.
Label “Shake Well Before Use” – mandatory to ensure dose uniformity.
Protect from excessive heat – store below 40 °C.
How Long Does Megestrol Take to Work?
The timeline for therapeutic response varies dramatically by indication.
Appetite Stimulation and Weight Gain
Initial response (increased food intake): Within 1–2 weeks of starting therapy.
Measurable weight gain: Typically evident by 3–4 weeks.
Maximum effect: May require 8–12 weeks of continuous treatment.
In a meta‑analysis of cancer cachexia trials, short‑term intervention (≤8 weeks) showed significant weight gain, and each 200 mg/day dose increment was associated with an additional 0.44 kg of weight gain (P = 0.005).
Cancer Treatment
Breast / endometrial cancer: At least 2 months of continuous therapy is considered an adequate trial.
Tumor response may be assessed via imaging and tumor markers.
Patient Counseling Point
Set realistic expectations: megestrol is not a quick fix. It is a supportive medication that gradually helps rebuild nutritional status and improve quality of life. Encourage patients to track food intake, weight, and energy levels in a diary.
Global Sourcing Tips for Megestrol Acetate API
For pharmaceutical manufacturers, ensuring a reliable, high‑quality supply of Megestrol Acetate Active Pharmaceutical Ingredient (API) is mission‑critical. Here’s what you need to know about the global sourcing landscape.
Leading Manufacturing Regions
Europe – Companies like Axplora (Farmabios, Italy) produce Megestrol acetate API under EU‑GMP, US‑FDA, and PMDA (Japan) approvals. Their specialty is steroid chemistry and handling high-potency APIs.
China – Shanghai Fosun Pharmaceutical, Hengkang Pharmaceutical, and Sino Biopharmaceutical operate GMP‑certified steroid API plants servicing global markets.
Regulatory Documentation to Demand
When vetting a supplier, insist on:
Certificate of Analysis (CoA) – confirming identity, purity, potency, and residual solvents.
Drug Master File (DMF) – on file with US‑FDA or equivalent authority.
Certificate of Suitability (CEP) – for European market access.
GMP Compliance Statement – current, not expired.
Site Audit Report – ideally from a recognized authority.
As one industry guide notes: “Vendors must demonstrate compliance with applicable cGMP standards, provide comprehensive regulatory documentation, and pass rigorous audits”.
Supply Chain Resilience Tips
Dual‑source qualification: Have at least two approved API suppliers to mitigate disruption.
Warehouse buffer stock: Maintain 3–6 months of safety stock.
Quality history review: Request batch failure rates, complaint records, and recall history.
Physical appearance: Verify that the API is a white to off‑white crystalline powder, consistent with pharmacopoeial specifications.
Megestrol for Special Populations and Emerging Research
Megestrol in the Elderly
Elderly patients are particularly vulnerable to megestrol’s adverse effects—especially thromboembolism and adrenal suppression. Starting doses should be conservative, and monitoring must be intensified. Despite these risks, megestrol remains a valuable option for geriatric cachexia when nutritional interventions have failed.
Megestrol in Bodybuilding – A Cautionary Tale
A disturbing trend has emerged of healthy young men using megestrol to stimulate appetite and “bulk up.” This is dangerous. A published case report describes a 24‑year‑old male who took MA 625 mg/day for 2 months, developed severe hypothalamic‑pituitary dysfunction, and experienced a catastrophic drop in testosterone (from 1,100 ng/dL to 66 ng/dL), depression, erectile dysfunction, and prolonged adrenal insufficiency. Three months after discontinuation, his testosterone was still undetectable (<3 ng/dL).
Warning: Megestrol is not a performance‑enhancing drug. The weight gained is predominantly adipose tissue—not muscle—and the hormonal damage can be long‑lasting.
Pediatric Use
Safety and efficacy in pediatric patients have not been established. Use in children is reserved for exceptional circumstances under specialist supervision.
Frequently Asked Questions About Megestrol
Q: Can I drink alcohol while taking megestrol?
A: There is no direct contraindication, but both alcohol and megestrol can affect the liver and blood glucose. Moderation is advised, and discuss with your physician.
Q: Does megestrol cause birth defects?
A: Yes. Megestrol is contraindicated in pregnancy. Women of childbearing potential must use effective contraception during therapy.
Q: Will megestrol make me gain muscle?
A: No. The weight gained is primarily fat mass, not lean muscle. It is not an anabolic steroid.
Q: Can megestrol be crushed?
A: Tablets can be crushed and mixed with food if swallowing is difficult. The oral suspension is an alternative for patients who cannot swallow tablets.
Q: How should I store megestrol?
A: Store at room temperature (20–25 °C / 68–77 °F) in a tightly closed container. Protect from heat above 40 °C (104 °F).
Conclusion
Megestrol (Megestrol Acetate) occupies a unique therapeutic niche at the intersection of oncology, endocrinology, and supportive care.
It is a drug of remarkable duality: capable of extending life in hormone‑sensitive cancers while restoring dignity and quality of life in patients ravaged by wasting syndromes. Yet its power demands respect.
The risks of thrombosis, adrenal suppression, and severe hormonal disruption are real and must be managed proactively.
Whether you are a clinician seeking to optimize a patient’s regimen, a compounder preparing a stable suspension, a sourcing manager navigating the global API market, or a patient striving to understand a newly prescribed medication, we hope this comprehensive guide has clarified the landscape for you.
At the heart of effective Megestrol therapy lies informed decision‑making. Understand the indications.
Respect the contraindications. Monitor vigilantly. And never, ever stop this drug abruptly without a plan.
If you found this guide valuable, bookmark it, share it with a colleague, and leave a comment below.
Together, we can elevate the standard of care for every patient who depends on this extraordinary molecule.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
